^
Association details:
| Biomarker: | IFNG expression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | bintrafusp alfa (M7824) (PD-L1 inhibitor, TGFβ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Consensus molecular subtype (CMS) as a novel integral biomarker in colorectal cancer: A phase II trial of bintrafusp alfa in CMS4 metastatic CRC.
Published date:
05/13/2020
Excerpt:
Although the efficacy for bintrafusp alfa and RT is low, changes in IFNγ signature provides a potential signal for refining therapeutic strategies based upon TGFβ enrichment in pts with mCRC.
DOI:
10.1200/JCO.2020.38.15_suppl.4084
Trial ID:
